Arena Pharmaceuticals, Inc.
NASDAQ: ARNA
$99.99
+$0.00 (+0.0%)
Closing Price on March 15, 2022
ARNA Articles
Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.
Published:
ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close up...
Published:
24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10 that had big upside potential for 2014. These are potentially the next great growth engines...
Published:
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
Published:
Jon OggWith the government shut down and with the debt ceiling debate breathing down everyone’s neck, investors have to be wondering what they should buy, sell and hold (or even avoid). Stocks have...
Published:
ThinkstockIt is not unusual to see most research on Wall Street pretty much line up either for or against a company. Analysts typically look at the same metrics in the balance sheet and the...
Published:
Last Updated:
U.S. equity markets opened higher this morning following upward revisions from the Bureau of Labor Statistics on non-farm payrolls in February and March and a larger-than-expected rise in payrolls in...
Published:
Last Updated:
ThinkstockDrug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) has withdrawn its application for European regulatory approval of its weight-loss drug Belviq. The drug was approved for use in the...
Published:
Last Updated:
U.S. equity markets opened lower this morning following news out of China that government is about to tighten restrictions on real estate transactions. The news pushed the Shanghai exchange down...
Published:
Last Updated:
U.S. equity markets opened lower this morning following a number of disappointing data releases in Europe and Asia. Eurozone PMI remains on the pessimistic side, with a reading of 47.9, and the...
Published:
Last Updated:
ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its...
Published:
ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change. You will just have to lose that weight the old-fashioned way through diet, exercise, and...
Published:
Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades and initiations seen from Wall S. research calls. We have calls in banks, solar, tech, biotech and more. Arch Coal Inc....
Published:
ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are obese or very overweight. Obesity-related medical conditions include...
Published:
Last Updated:
U.S. equity markets opened about flat this morning following the holiday weekend in the U.S. Foreign markets were also more or less mixed. In Europe, the German and eurozone economic indexes came in...
Published:
Last Updated: